Advertisement BodyTel signs distribution agreement with Sanisa - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

BodyTel signs distribution agreement with Sanisa

BodyTel Scientific, through its wholly owned subsidiary BodyTel Europe, has entered into an exclusive distribution agreement with Sanisa.

Beginning in the third quarter of 2008, BodyTel’s new partner Sanisa will begin offering BodyTel’s blood glucose monitoring and diabetes management system, GlucoTel, in Spain and Portugal.

Pursuant to the terms of the distribution agreement, BodyTel granted Sanisa the right to exclusively market GlucoTel in those countries for a term of one year.

BodyTel’s GlucoTel system is a complete telemedical blood glucose monitoring and diabetes management system, supporting patients and healthcare professionals in the treatment and control of diabetes and other associated disorders.

Stefan Schraps, CEO of BodyTel, said: “Focused on new technologies in the medical-scientific arena, Sanisa’s advisors have a breath of knowledge and experience in the diabetes sector. They are a perfect partner to introduce our diabetes management solution within Spain and Portugal.”